ANIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Anixa Biosciences's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $24.61 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Anixa Biosciences's Book Value per Share for the quarter that ended in Jan. 2024 was $0.77. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Anixa Biosciences's Debt-to-Equity for the quarter that ended in Jan. 2024 was 0.01.
The historical data trend for Anixa Biosciences's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences Annual Data | |||||||||||||||||||||
Trend | Oct14 | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | |||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | 5.24 | 8.76 | 35.44 | 29.05 | 24.34 |
Anixa Biosciences Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 27.79 | 26.81 | 25.52 | 24.34 | 24.61 |
Anixa Biosciences (NAS:ANIX) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Anixa Biosciences's Book Value per Share for the quarter that ended in Jan. 2024 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (24.605 | - | 0) | / | 31.7544 | |
= | 0.77 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Anixa Biosciences's Debt-to-Equity for the quarter that ended in Jan. 2024 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.054 | + | 0.108) | / | 24.605 | |
= | 0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Anixa Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Amit Kumar | director, officer: Chief Executive Officer | C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660 |
Michael Catelani | officer: COO & CFO | 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025 |
Titterton Lewis H Jr | director | 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866 |
Arnold M Baskies | director | 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003 |
Emily Gottschalk | director | 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118 |
John J Monahan | director | |
David Cavalier | director | C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677 |
Richard H Williams | director | C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108 |
Dale Fox | director | 929 NOWITA PLACE, VENICE CA 90291 |
Andrea Belz | director | 1011 ALTA VISTA DRIVE, ALTADENA CA 91001 |
Tisha Stender | officer: Chief Operating Officer | 900 WALT WHITMAN ROAD, MELVILLE NY 11747 |
Robert Andrew Berman | officer: President and CEO | C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025 |
John H. Roop | officer: Sr. Vice President-Engineering | C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747 |
Bruce F Johnson | director | 20 S. WACKER DR, CHICAGO IL 60606 |
Kent B. Williams | director | C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747 |
From GuruFocus
By PRNewswire PRNewswire • 05-22-2023
By PRNewswire PRNewswire • 02-21-2023
By PRNewswire PRNewswire • 08-31-2022
By PRNewswire PRNewswire • 04-17-2023
By PRNewswire • 11-27-2023
By PRNewswire • 08-07-2023
By ACCESSWIRE • 08-10-2023
By PRNewswire PRNewswire • 04-17-2023
By PRNewswire • 01-23-2024
By PRNewswire • 10-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.